Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. | Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice